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AbstrACt
Introduction Compared with the rest of the UK and 
Western Europe, England has high rates of the infectious 
disease tuberculosis (TB). TB is curable, although 
treatment is for at least 6 months and longer when 
disease is drug resistant. If patients miss too many doses 
(non- adherence), they may transmit infection for longer 
and the infecting bacteria may develop resistance to the 
standard drugs used for treatment. Non- adherence may 
therefore risk both their health and that of others. Within 
England, certain population groups are thought to be at 
higher risk of non- adherence, but the factors contributing 
to this have been insufficiently determined, as have the 
best interventions to promote adherence. The objective 
of this study was to develop a manualised package of 
interventions for use as part of routine care within National 
Health Services to address the social and cultural factors 
that lead to poor adherence to treatment for TB disease.
Methods and analysis This study uses a mixed- methods 
approach, with six study components. These are (1) 
scoping reviews of the literature; (2) qualitative research 
with patients, carers and healthcare professionals; (3) 
development of the intervention; (4) a pilot randomised 
controlled trial of the manualised intervention; (5) a 
process evaluation to examine clinical utility; and (6) a cost 
analysis.
Ethics and dissemination This study received ethics 
approval on 24 December 2018 from Camberwell St. 
Giles Ethics Committee, UK (REC reference 18/LO/1818). 
Findings will be published and disseminated through 
peer- reviewed publications and conference presentations, 
published in an end of study report to our funder (the 
National Institute for Health Research, UK) and presented 
to key stakeholders.
trial registration number ISRCTN95243114
secondary identifying numbers University College 
London/University College London Hospitals Joint Research 
Office 17/0726.
National Institute for Health Research, UK 16/88/06.
IntroduCtIon
Against a background of rising tuberculosis 
(TB) in the 1990s and 2000s, the need for 
a comprehensive approach to TB control 
in England was deemed necessary by Public 
Health England and the National Health 
Service (NHS) England. In January 2015, 
these bodies jointly launched the ‘Collabora-
tive Tuberculosis Strategy for England 2015–
2020’.1 This seeks to reduce TB incidence, 
decrease health inequalities and ultimately 
contribute to international efforts to elimi-
nate TB as a public health problem. Ensuring 
strengths and limitations of this study
 ► Patient- centred, mixed- methods approach, based 
on a robust understanding of the evidence on social, 
cultural and personal factors that influence adher-
ence to medication to treat tuberculosis (TB).
 ► Evidence and experience of adherence captured 
from a variety of perspectives from across the 
UK, including patients, their carers and healthcare 
workers.
 ► Generalisable patient population of individuals at 
risk of non- adherence across low TB incidence 
settings.
 ► Development of a pragmatic and easy- to- use tool 
that captures the best evidence on adherence and 
allows its application in the clinic setting.
 ► The study culminates in a pilot trial of the manual-
ised intervention; a larger subsequent definitive trial 
is needed to test whether the intervention is effica-
cious and cost- effective beyond any initial conclu-
sions regarding validity and feasibility derived from 
the pilot.
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that people can take all of their medication as prescribed 
is one of the strategy’s priorities, as poor adherence to 
treatment for TB is a driver of worse patient outcomes,2–9 
increases the risk of transmission (due to delayed sputum 
culture conversion)10 and can promote the development 
of drug resistance.3 11–16 Subsequent National Institute for 
Health and Care Excellence (NICE) guidance noted the 
lack of robust TB research in this area.17
Barriers to optimal adherence to treatment for TB may 
occur for a number of reasons. These include
 ► Patient- related factors, including perceptions and 
beliefs.
 ► Cultural influences and current mental state.
 ► Structural economic factors and social support 
networks.
 ► Health service factors that include treatment 
complexity as well as accessibility of those services 
and the relationships patients develop with service 
providers.18 19
Non- adherence is not a single issue and may take 
various forms, for example, suboptimal implementation 
(skipping doses) or stopping treatment early (eg, as soon 
as a patient feels better.).20
Although a series of studies have been undertaken 
to define the population groups most at risk of non- 
adherence,19 it is currently difficult, prior to starting 
medication, to identify who may struggle with taking 
treatment as prescribed. To date, methods to support 
treatment address some, but not all, of the important 
underlying reasons for poor adherence. For example, 
the WHO’s recent focus on digital technologies reflects 
our attention on individual- level determinants of adher-
ence and reminder/observation- based systems21; far less 
research has addressed the social and structural barriers 
to staying on TB treatment.
In the UK, the development of an intervention to 
support adherence to treatment that is sensitive to the 
individual’s cultural background and social circum-
stances, and can be routinely delivered within the NHS, 
is critical. To this purpose, a mixed- methods, patient- 
centred, approach to the study of the modifiable factors 
that influence patients’ adherence to treatment of TB is 
required.
MEthods And AnAlysIs
research question
Can a manualised package of intervention be developed 
to help overcome the social and cultural factors that lead 
to poor adherence to treatment in NHS patients in the 
UK with active TB?
Aim
To develop, pilot and evaluate process and interim 
outcomes for an effective manualised intervention that 
improves the likelihood of adherence to treatment 
among NHS patients at risk of poor adherence due to 
social, cultural and structural factors.
objectives
1. Synthesise current knowledge on (1) determinants of 
adherence to treatment for TB and (b) interventions 
that can support adherence, with particular emphasis 
on social and cultural barriers (scoping review and 
conceptual framework).
2. Apply a conceptual framework of adherence endorsed 
by NICE guidelines (the perceptions and practicalities 
(PAPA) approach)18 to elucidate and address the per-
sonal, sociocultural and health systems context, mech-
anisms and pathways of poor adherence among NHS 
patients with TB (formative research).
3. Develop a manualised intervention (a series of system-
atic actions applied on the basis of a patient’s needs 
assessment) with multiple components that can iden-
tify (1) NHS patients most at risk of non- adherence, 
(2) the salient modifiable barriers and (3) the tailored 
support mechanisms required to meet individual pa-
tient needs by matching appropriate interventions to 
specific barriers, as recommended by NICE (Devel-
opment of Intervention). A manualised intervention 
was considered to be a suitable approach to managing 
adherence in TB, as it will enable a set of measures to 
be applied consistently within different NHS settings 
that will aid both clinicians and patients throughout 
the treatment journey. The content of the interven-
tion will use existing support measures, employed in 
a systematic and structured way, and may also include 
any new interventions that are developed in response 
to the formative research. It will be compared with 
normal care.
4. Pilot the intervention package in people at risk of 
poor adherence to define how the components work 
in combination and separately (pilot study).
5. Evaluate the process of implementation of this inter-
vention through describing the challenges and facilita-
tors in delivering the package as intended (fidelity and 
reach) and assessing the impact of the intervention 
through evaluation of adherence indicators (process 
evaluation).
6. Use the findings of the pilot to assess the costs of deliv-
ering the manualised intervention in an NHS setting 
and to guide development of a proposal for a full ran-
domised controlled trial (RCT).
study dEsIgn
This study uses a mixed- methods approach. There are 
six subsections, reflecting the six objectives: (1) scoping 
review and conceptual framework, (2) formative research, 
(3) development of intervention, (4) pilot study, (5) 
process evaluation and (6) cost analysis and future work. 
Although the different elements are described sepa-
rately further, the research activities for each will overlap, 
and some will run concurrently. The full programme of 
work and relationships between subsections is shown in 
figure 1. This paper reflects protocol V.4.0 (26 September 
2019).22
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Figure 1 IMPACT study. The six mixed- methods elements of the IMPACT study and the relationships between them. The 
study is guided by a steering group which has oversight over the entire process and culminates in a pilot study with associated 
evaluatory elements. IMPACT, Intervening with a Manualised Package to Achieve Treatment Adherence in People with 
Tuberculosis; NHS, National Health Service.
scoping review
To underpin the development of the manualised inter-
vention, the first study subsection will undertake litera-
ture reviews to answer the following research questions:
1. What personal, social, cultural, health systems- related 
and structural factors affect individuals’ ability to ad-
here to treatment for TB?
2. What kinds of intervention have been developed to 
address the multiple levels (personal, social, cultural, 
systems and structural) at which barriers to adherence 
may operate?
3. What is the evidence for the successful impact of inter-
ventions to address barriers to adherence to treatment 
for TB?
These questions will be answered through the three 
following reviews:
1. A scoping review of qualitative studies that examine 
the personal, social, cultural, health systems- related 
and structural factors affecting adherence to treatment 
for TB from the perspectives of adult patients, caregiv-
ers or healthcare providers, as well as studies that eval-
uate interventions to support adherence to treatment 
for TB. Data from all settings will be considered, but 
with a particular focus on low incidence, high income 
settings.
2. A critical review of quantitative studies examining the 
personal, social, cultural, health systems- related and 
structural factors affecting adherence to treatment 
for TB. This review focuses on low incidence, high in-
come, settings and observational study designs. Given 
the scoping nature of the review, findings will be de-
scriptively analysed and not be stratified or disaggre-
gated, for example, by site of disease. All relative and 
absolute measures of effect will be extracted.
3. A critical review of quantitative studies that have ex-
amined the effectiveness of interventions to improve 
adherence in people taking treatment for TB, build-
ing on existing systematic reviews, including the pro-
vision and delivery of information and/or education; 
enablers and/or incentives; social support; and case 
management approaches. Given the more limited lit-
erature, both observational studies and clinical trials 
will be included, from all settings. Findings will be de-
scriptively analysed.
Together, these three reviews will enable us to conduct 
a critical interpretive synthesis of findings from qualita-
tive and quantitative studies examining the assumptions 
and mechanisms of effect underlying interventions to 
improve adherence to treatment for TB. Further details 
on the reviews are available in the full protocol.22
Formative research
Formative research methods, recruitment and eligibility
In line with findings from the scoping review, we will 
develop topic guides for qualitative interviews exploring 
current models of TB service delivery in the study sites, 
providers’ views on the barriers and facilitators for treat-
ment adherence, and TB patients’ and their family 
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members’ experiences of starting and staying on treat-
ment. Details about these guides are available within the 
full protocol.22 The thematic analysis of these interviews 
will complement insights gained from the scoping reviews, 
which will allow us to refine a conceptual framework of 
adherence building on the PAPA.18 Approximately 50 
participants will be enrolled.
Adults (aged 18 and over) who are currently taking or 
recently completed treatment will be identified by the local 
TB service at four UK sites (Southampton, Edinburgh, 
Central London and East London)) and will be asked 
to take part in the study. The services have been chosen 
for their patient diversity, geographical spread and as 
reflecting the national TB picture. The patient group will 
be enriched with people who have been poorly adherent 
to treatment, although we will also include patients who 
report full adherence so that we can capture what may 
have enabled them to take treatment as prescribed. With 
patient consent, family members and/or carers will also 
be approached and asked to participate.
Health and social care workers from both primary 
and secondary care settings will be directly approached 
by researchers and invited to be interviewed. All those 
approached will be aged 18 or over and involved in TB 
management and care.
Data collection methods
Three different methods of data collection will be used to 
undertake the formative research.
In-depth interviews: patients and family members/carers
These will be conducted as individual interviews with 
approximately 30 participants, using a topic guide. The 
areas to be explored are self- perception, personal beliefs 
and practices related to medicine- taking, health literacy 
and health- seeking behaviour, social support, cultural 
norms around health- seeking behaviour, and financial 
and other structural barriers.
Testing of Beliefs about Medicines Questionnaires (BMQ) and 
Brief Illness Perception Questionnaire (BIPQ) questionnaires with 
patients for their suitability
To ensure that the validated questionnaires (ie, 23BMQ 
and the 24BIPQ) are accessible and acceptable to patients, 
we will also conduct cognitive interviews with 10 patients. 
We will then have confidence to use them in the later 
pilot study to assess patient PAPA affecting adherence 
to anti- TB therapy. These will explore self- perception, 
personal beliefs and practices related to medicine- taking.
Semistructured interviews: healthcare providers
These will be undertaken with healthcare providers 
responsible for multiple aspects of TB care (doctors, 
nurses, social workers, directly observed therapy (DOT) 
providers, managers and administrators). They will focus 
on providers’ perceptions of factors affecting patient 
understanding of TB and its treatment, service delivery 
models including staffing, organisation of care and 
communication. We will interview four to six providers at 
each site, aiming for a total of 20 interviews.
We will use a framework approach25 to facilitate initial 
analysis of the interview transcripts. Short patient case 
studies will be created for each patient interview. Data 
on health systems issues gained through mapping patient 
pathways and provider interviews will be organised using 
a deductive approach, with appropriate visual pathways.
development of the manualised intervention
Intervention development process
The data collected from the scoping reviews and forma-
tive research will be presented to, and synthesised by, 
an intervention development group (IDG). A manual-
ised intervention will be developed to identify (1) NHS 
patients most at risk of non- adherence, (2) their salient 
modifiable barriers and (3) the tailored support mech-
anisms that meet individual patient needs by matching 
appropriate interventions to these specific barriers.
The IDG will aim to include
 ► Patients (in particular the homeless, ethnic minori-
ties, migrants new to the UK, and patients with drug 
resistant TB).
 ► Family members/significant others of affected 
persons.
 ► Members of the public.
 ► Healthcare professionals (from both primary and 
secondary care).
 ► Other professionals who work with patients/commu-
nities affected by TB.
The constitution of the IDG will enable a coproduction 
approach to ensure that the intervention is pragmatic, 
can be delivered within the context of existing care path-
ways, and is of benefit to service users and those who are 
likely to access the intervention.
Intervention contents
The manualised intervention is likely to consist of a 
screening and assessment tool, in addition to a package of 
measures that can be tailored to the needs of individual 
patients from different population groups.
As patterns of adherence may be irregular over time, 
it is intended that the manualised intervention will be 
administered to all patients at each patient review. The 
tool thus needs to be quick and easy to administer. It 
may be electronically linked to patient records, enabling 
a comprehensive picture of the risk of possible non- 
adherence to be developed for each patient, as well as 
within a clinic population. The various delivery options 
for the intervention (such as using paper or an app) will 
be considered during its development stage.
The menu of supportive measures may, for example, 
include
 ► Informational intervention: for example, providing 
a convincing story setting out the rationale and 
ongoing need for medication, addressing concerns 
about potential adverse effects and consequences of 
treatment and what to do if such events occur (eg, 
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the participants will be informed that it is possible to 
change their treatment regimens to alternatives).26
 ► Practicalities and capability- based interventions: video- 
observed therapy (VOT); DOT; reminders, including 
text messaging; automated methods for monitoring 
and feedback, including electronic dosette boxes; use 
of a medication app; incentives, for example, finan-
cial and food vouchers; mitigation; and management 
of drug toxicity due to treatments.
 ► Social and system interventions: offering flexibility 
in appointments; enhanced guidance on ‘navigating’ 
clinic pathways; signposting patients to relevant 
services, for example, housing, drug and alcohol 
services, and social care; and providing peer support.
Piloting the intervention
Study design, recruitment and eligibility
Once the intervention is developed, proof of concept is 
required within the real world. This will be undertaken 
using a non- blinded cluster randomised pilot study that 
compares the manualised intervention to the usual stan-
dard of care in four London clinics treating TB. Two 
clinics will be randomly allocated to the intervention 
and two to standard of care. In the latter, the amount of 
support provided to patients is based on perceived need, 
as identified by a nurse- led review and a needs assess-
ment. Most patients will have supported self- administered 
therapy, while others will be offered DOT and/or VOT if 
this is felt to be appropriate. We anticipate enrolment to 
commence in January 2020.
All consecutive patients aged 18 or over who are 
about to start treatment for TB, irrespective of the site 
of disease, will be approached to take part in the study. 
We will exclude individuals who are unable to provide 
informed consent, those already on treatment and those 
who are not expected to live for the duration of the 
study (a minimum of 6 months from starting treatment). 
Within the pilot study, it is essential to capture the entire 
treatment period for each patient in order to assess the 
effectiveness of the intervention. Due to the nature of the 
TB patient population in the UK, patients are likely to 
include people at greater risk of poor adherence, such 
as migrants newly arrived in the UK, people whose first 
language is not English, people with a mental health 
disorder, people taking immunosuppressive therapy or 
known to have immunodeficiency, those with a previous 
history of treatment for TB, or poor adherence with 
anti- TB medication, and people with a current or previous 
history of drug or alcohol misuse.
The purpose of the pilot study was not formal hypoth-
esis testing. Given this, a target sample size of 80 patients 
enrolled (20 per site) was identified for the pilot study 
as providing useful information that can help determine 
whether the intervention will be deliverable within a clin-
ical setting. It will also guide the development of a possible 
larger definitive study using the intervention. The four 
TB clinics of interest (in East and North London) each 
treat in excess of 60 relevant patients per annum.
Based on usage of DOT within the clinic populations 
seen at the treatment sites (ie, individuals currently iden-
tified as needing adherence support), we estimate that 
around 33% of patients will be at risk of non- adherence. 
Taking this as a minimum (as the manualised interven-
tion is likely to be more sensitive than current risk assess-
ments), we would expect that at least 26 of the 80 patients 
recruited will be identified as requiring adherence 
support. This sample size allows us to measure consent 
to enrolment for 80 individuals, data completeness for 
adherence and treatment outcomes for 80 individuals, 
data on acceptability and feasibility of the intervention 
package for around 40 individuals, and data on accept-
ability and feasibility of adherence support for at least 
26 individuals (13 receiving the manualised intervention 
and 13 standard care).
Outcomes of the pilot
The primary outcome of the study will be level of adher-
ence, measured as the proportion of prescribed doses 
taken and assessed at 6 months from the start of treat-
ment. In addition to this primary outcome, a number of 
secondary outcomes will also be measured, as follows:
1. Proportion consenting to the study.
2. Completeness of data for measures of adherence.
3. Proportion of patients withdrawing during the study 
and the reasons why.
4. Proportion of patients identified as needing adher-
ence support in the intervention arm.
5. Proportion of patients offered adherence support 
and accepting it in the intervention arm.
6. Documentation of which adherence- promoting ac-
tivities have been implemented among patients both 
in the standard of care and intervention arm, and 
when.
7. Detailed treatment implementation information: for 
example, proportion of patients completing treat-
ment, proportion of patients still on treatment after 
9 months or at study completion (whichever is the 
earlier).
8. Patterns of adherence (implementation and 
discontinuation).
9. Impact of manualised intervention on maintaining 
adherence over the duration of treatment.
10. Process variables: adherence- related PAPA.
Measures of adherence
Our primary measure of adherence will be data obtained 
from medication monitoring boxes.27 The boxes will not 
be set up act as a reminder system. Other measures will 
also be used and compared with this. These will include 
pill counts (the remaining medication in the box at the 
end of each month) and also patient- reported adherence, 
where we will ask patients to estimate how many doses 
they have missed in the last month. In the case of DOT or 
VOT methods being used, a record of missed doses will 
be kept.
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Table 1 Power calculation for the pilot study, given a 
sample size of 80 individuals (40 per arm), across a range of 
baseline levels of adherence and absolute increases in that 
level
Baseline adherence Absolute increase Power
70 30 0.98
60 30 0.88
50 30 0.82
80 20 0.86
70 20 0.61
60 20 0.49
90 10 0.54
80 10 0.24
70 10 0.18
Administration of the manualised intervention
The patient’s case manager (usually the TB clinic nurse), 
plus a study research nurse, will apply the intervention in 
partnership with the patient to identify whether personal, 
sociocultural and/or systems risk factors are present that 
suggest likely poor adherence with treatment. If these 
are identified, then the relevant measures outlined in 
the manualised intervention that may mitigate these will 
be reviewed and implemented with the agreement of 
the participant. These will be continued throughout the 
course of treatment or stopped if no longer deemed to be 
relevant or required on reassessment.
Study schedule of visits
Study subjects will be seen at weeks 0, 2, 4, 8, 12, 16, 20 
and 24 (earliest date of treatment completion). Should 
they require ongoing treatment after 6 months, they will 
be seen as clinically indicated. At each review, adher-
ence assessments will be performed, in addition to an 
assessment of PAPA, the completion of the BMQ and 
the EQ- 5D- 5L Quality of Life questionnaires23 28 and 
the GAD-729 and PHQ-930 to assess anxiety and depres-
sion. The manualised intervention will be applied if the 
patient is attending a clinic that has been randomised 
to the intervention arm. All data will be collected by the 
research nurse using standardised forms.
Follow-up
Most patients who do not have clinically important drug- 
resistant disease receive 6 months of treatment. To allow 
for treatment interruptions, patients within the pilot 
study will be followed up to either treatment completion 
or for a total of 9 months from starting anti- TB therapy.
Analysis and interpretation
Where possible, univariable analyses will be undertaken 
to compare each outcome measure listed between 
study arms (intervention and control). For the primary 
outcome (adherence), the mean percentage value will 
be reported by arm (intervention and control) and histo-
grams will be used to describe the distribution of values 
by study arm. Binary secondary outcomes will be reported 
by the proportion of individuals achieving the outcome 
within each arm. The need to adjust for clustering by site 
and clinical care provider will be assessed using the cluster 
summary method (a t- test) to compare the cluster means 
or proportions (as appropriate, between arms). An assess-
ment of the balance in baseline characteristics between 
the study arms will also be conducted. If randomisation 
has failed to evenly distribute key characteristics (eg, age, 
sex, ethnicity or other factors identified as important 
during the scoping reviews), then the cluster means or 
proportions will be adjusted for these differences before 
applying the t- test. This two- stage approach to analysis 
is described by Hayes and Moulton.31 We recognise that 
adherence data may be highly skewed and thus may 
require compensatory analytical approaches.
The analysis of the first three of our secondary outcomes 
will address the feasibility of a definitive trial following a 
similar design to the pilot. Analysis of secondary outcomes 
4–6 addresses the intervention, and complements the 
process evaluation (see below). Analysis of the primary 
outcome and final secondary outcomes around treatment 
adherence and completion provides initial information—
given the modest sample size—concerning the effective-
ness of the intervention, and may assist the sample size 
calculation for the definitive trial. They can also offer an 
alert in the unlikely event that the intervention is harmful.
Power calculation
Although we are undertaking a pilot study and thus the 
numbers enrolled are small, table 1 indicates the power 
of our primary analysis to detect a range of absolute 
increases in adherence (10%–30%) from a variety of 
baseline values (50%–90%).
Process evaluation
Evaluation method
We will evaluate the implementation process by analysing 
the challenges and facilitators in delivering the package. 
The impact of the intervention will be assessed by evalu-
ation of adherence indicators. We will use the findings of 
the pilot to assess the costs of delivering the manualised 
intervention in an NHS setting and to guide development 
of a proposal for a full RCT.
The process evaluation will consist of a description 
of the process of intervention implementation. It will 
assess how well the manualised intervention achieves its 
intended aim compared with standard care.
We will consider
1. The fidelity of the intervention as delivered in compar-
ison to how it was designed and envisaged.
2. The reach of the intervention (the proportion of the 
target group receiving it).
3. The barriers to facilitating implementation of the in-
tervention and how these can be addressed.
4. The pre- existing factors that facilitated implementation.
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Process measures, recruitment and eligibility
Process measures for each element of the package will 
be developed once the manual development has been 
completed and will be used to assess success. They will 
include acceptability, uptake and change in practice. 
We will work with patients and staff separately at all four 
London sites. We will interview 20 patients (5 at each study 
site, ie, 10 from each arm) and, if possible, 20 healthcare 
workers (5 at each site). The patients will be selected 
within each site using purposeful sampling of clinic lists 
of every patient with active TB, to enable us to reflect the 
demographic spread of patients.
Key outputs will include a qualitative evaluation of 
delivery, the development of a narrative description of 
the process of intervention implementation and main-
tenance, and a quantitative assessment of adherence- 
related PAPA within intervention and control groups.
We will invite participation in the process evalua-
tion from patients enrolled in the pilot study or staff 
members treating patients at one of the four London 
sites also involved in delivering the pilot study. They will 
be included if they are aged 18 years or over and able 
to provide informed consent. This will include probing 
anticipated versus real- life delivery of the intervention.
Cost analysis and future work
In order to generate realistic estimates of the cost of 
the intervention, cost data from the NHS perspective 
will be collected during the pilot study using a cost data 
collection tool used by health economists (the Client 
Service Receipt Inventory) modified for TB.32
After the pilot study and process evaluation have been 
completed, a final intervention package will be designed 
for use in a definitive RCT of the manualised package 
of interventions. The design of this final package will be 
based on the results of the process evaluation and the 
experience gained during the piloting of the interven-
tion, modifying the definitive trial design and/or data 
collection accordingly.
PAtIEnt And PublIC EngAgEMEnt
As documented previously, patient representatives will 
sit on the IDG for the study. In addition, TB Alert, the 
UK’s only national TB charity, has membership of the 
IDG. The role of the IDG, which will meet regularly 
throughout the study, is described in the section Devel-
opment of the manualised intervention. At the end of 
the study, the IDG will be involved in commenting on 
the findings and contributing to the dissemination plan.
EthICs, sPonsorshIP, ContACt dEtAIls And 
dIssEMInAtIon
The study is sponsored by the Joint Research Office 
of University College London and University College 
London Hospitals. This study received ethics approval on 
24 December 2018 from the Camberwell St Giles Ethics 
Committee (REC reference 18/LO/1818; Level 3, Block 
B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK;+44 
(0)207104 8204;  NRESCommittee. London- Camber-
wellStGiles@ nhs. net). Findings will be published and 
disseminated through peer- reviewed publications and 
conference presentations, published in an end- of- study 
report to our funder (the National Institute for Health 
Research, UK) and presented to key stakeholders.
For public enquiries, please contact Marcia Darvell, 
IMPACT Study Project Co- ordinator, Respiratory Medi-
cine, The Royal Free London NHS Foundation Trust, 
UCL Medical School Building, Rowland Hill Street, 
London, NW3 2PF, UK;+4420 8016 8375;  m. darvell@ ucl. 
ac. uk
For scientific enquiries, please contact the Chief Inves-
tigator Professor Marc Lipman (The Royal Free London 
NHS Foundation Trust and University College London), 
Respiratory Medicine, The Grove Centre, The Royal Free 
London NHS Foundation Trust, Rowland Hill Street, 
London, NW3 2PF, UK;+4420 7472 6452;  marclipman@ 
nhs. net.
dAtA shArIng stAtEMEnt
The datasets generated during and/or analysed during 
the current study will be available on request in a deiden-
tified format and after publication of study outcomes and 
associated permission from the funder. Requests for data 
should be directed to Professor Marc Lipman as per the 
contact details previously mentioned.
ConClusIon
Our study will develop and pilot a manualised interven-
tion to improve adherence to treatment for TB in the UK 
using a mixed- methods, patient- centred and provider- 
informed approach. This will enable us to begin to under-
stand what motivates patients’ treatment behaviour, while 
ensuring deliverability within the NHS. Our work is based 
on a robust understanding of the evidence on social, 
cultural and personal factors that influence adherence, 
and the interventions that are most effective in addressing 
these. The study reflects the geographical spread of TB 
in the UK and captures not only patient and expert clin-
ical and academic experience but also that of family and 
carers to develop the intervention. A key feature of the 
study is the coproduction of a pragmatic and easy- to- use 
tool that uses the best evidence on adherence and allows 
its application in the clinic setting in a dynamic and iter-
ative way.
Although the final pilot study may be limited to a 
relatively small sample size, it is hoped that its broad 
patient- centred perspective will make a useful contribu-
tion to our understanding of, and ability to deal effec-
tively with, the risks of non- adherence to TB treatment 
in a population that can find this challenging. As many 
of the factors influencing adherence are likely to be 
generalisable to patients with other conditions in both 
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high and low resource settings, this study also has the 
potential to inform adherence interventions in other 
disease areas.
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